Literature DB >> 24481324

Nonalcoholic fatty liver disease is a negative risk factor for prostate cancer recurrence.

Won-Mook Choi1, Jeong-Hoon Lee, Jung-Hwan Yoon, Cheol Kwak, Young Ju Lee, Young Youn Cho, Yun Bin Lee, Su Jong Yu, Yoon Jun Kim, Hyeon Hoe Kim, Hyo-Cheol Kim, Sung Yong Cho, Seung Bae Lee, Hyeon Jeong, Chung Yong Kim, Hyo-Suk Lee.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is closely related to the metabolic syndrome, which is associated with an increased risk of various malignancies. In this study, we investigated the association between NAFLD and prostate cancer biochemical recurrence (BCR) after radical prostatectomy. Consecutive prostate cancer patients who underwent radical prostatectomy were enrolled from two hospitals in Korea and randomly assigned to the training (n=147) or validation set (n=146). The presence of NAFLD, BMI, preoperative prostate-specific antigen, and histological findings including Gleason score (GSc) were analyzed in regard to their association with BCR. NAFLD was diagnosed based on ultrasonography or unenhanced computed tomography images. BCR-free survival rates were calculated using the Kaplan-Meier method. In the training set, 32 (21.8%) patients developed BCR during a median follow-up period of 51 (inter-quartile range, 35-65) months. In the multivariate analysis, the presence of NAFLD (hazard ratio (HR), 0.36; 95% CI, 0.14-0.97; P=0.04) was an independent negative predictive factor of BCR after adjustment for pathological GSc. Applied to the validation set, the presence of NAFLD maintained its prognostic value for longer time-to-BCR (HR, 0.17; 95% CI, 0.06-0.49; P=0.001). In the subgroup analysis of patients with NAFLD, NAFLD fibrosis score was a single independent negative predictor for BCR (HR, 0.54; 95% CI, 0.30-0.98; P=0.04). Our study demonstrated that NAFLD may play a protective role against BCR after radical prostatectomy for prostate cancer. Further study is warranted to elucidate the mechanism of protective effect in patients with NAFLD.

Entities:  

Keywords:  biochemical recurrence; nonalcoholic fatty liver disease; prostate cancer; radical prostatectomy

Mesh:

Year:  2014        PMID: 24481324     DOI: 10.1530/ERC-14-0036

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  7 in total

1.  The likelihood of having a serum PSA level of ≥2.5 ng/mL according to the degree of fatty liver disease in a screened population.

Authors:  Jong Hyun Yoon; Hee Jo Yang; Jae Heon Kim; Seung Whan Doo; Won Jae Yang; Jiyoung Hwang; Seong Sook Hong; Suyeon Park; Dae Yeon Cho
Journal:  Can Urol Assoc J       Date:  2015-12-14       Impact factor: 1.862

2.  Nonalcoholic fatty liver disease: a negative risk factor for colorectal cancer prognosis.

Authors:  Jie You; Sha Huang; Gui-Qian Huang; Gui-Qi Zhu; Rui-Min Ma; Wen-Yue Liu; Ke-Qing Shi; Gui-Long Guo; Yong-Ping Chen; Martin Braddock; Ming-Hua Zheng
Journal:  Medicine (Baltimore)       Date:  2015-02       Impact factor: 1.889

3.  Is nonalcoholic fatty liver disease associated with the development of prostate cancer? A nationwide study with 10,516,985 Korean men.

Authors:  Yoon Jin Choi; Dong Ho Lee; Kyung-Do Han; Hyuk Yoon; Cheol Min Shin; Young Soo Park; Nayoung Kim
Journal:  PLoS One       Date:  2018-09-19       Impact factor: 3.240

4.  The Identification of Critical m6A RNA Methylation Regulators as Malignant Prognosis Factors in Prostate Adenocarcinoma.

Authors:  Jiaju Xu; Yuenan Liu; Jingchong Liu; Tianbo Xu; Gong Cheng; Yi Shou; Junwei Tong; Lilong Liu; Lijie Zhou; Wen Xiao; Zhiyong Xiong; Changfei Yuan; Zhixian Chen; Di Liu; Hongmei Yang; Huageng Liang; Ke Chen; Xiaoping Zhang
Journal:  Front Genet       Date:  2020-12-04       Impact factor: 4.599

Review 5.  Non-Alcoholic Fatty Liver Disease and Extrahepatic Cancers: A Wolf in Sheep's Clothing?

Authors:  Athanasia Mitsala; Christos Tsalikidis; Konstantinos Romanidis; Michail Pitiakoudis
Journal:  Curr Oncol       Date:  2022-06-25       Impact factor: 3.109

Review 6.  Non-Alcoholic Fatty Liver Disease and Extra-Hepatic Cancers.

Authors:  Claudia Sanna; Chiara Rosso; Milena Marietti; Elisabetta Bugianesi
Journal:  Int J Mol Sci       Date:  2016-05-12       Impact factor: 5.923

7.  Selective Estrogen Receptor Modulator-Associated Nonalcoholic Fatty Liver Disease Improved Survival in Patients With Breast Cancer: A Retrospective Cohort Analysis.

Authors:  Qiufan Zheng; Fei Xu; Man Nie; Wen Xia; Tao Qin; Ge Qin; Xin An; Cong Xue; Roujun Peng; Zhongyu Yuan; Yanxia Shi; Shusen Wang
Journal:  Medicine (Baltimore)       Date:  2015-10       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.